Genomictree Inc. (KOSDAQ:228760)
South Korea · Delayed Price · Currency is KRW 28,100
+300 (1.08%)
Dec 10, 2025, 3:30 PM KST
Genomictree Revenue
Genomictree had revenue of 896.83M KRW in the quarter ending September 30, 2025, with 29.34% growth. This brings the company's revenue in the last twelve months to 3.76B, up 70.89% year-over-year. In the year 2024, Genomictree had annual revenue of 2.36B, down -30.89%.
Revenue (ttm)
3.76B
Revenue Growth
+70.89%
P/S Ratio
179.58
Revenue / Employee
n/a
Employees
n/a
Market Cap
675.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.36B | -1.06B | -30.89% |
| Dec 31, 2023 | 3.42B | -26.45B | -88.56% |
| Dec 31, 2022 | 29.87B | 24.73B | 481.09% |
| Dec 31, 2021 | 5.14B | 3.90B | 314.87% |
| Dec 31, 2020 | 1.24B | 957.22M | 339.89% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |